1. Home
  2. SEAT vs OMER Comparison

SEAT vs OMER Comparison

Compare SEAT & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SEAT
  • OMER
  • Stock Information
  • Founded
  • SEAT 2001
  • OMER 1994
  • Country
  • SEAT United States
  • OMER United States
  • Employees
  • SEAT N/A
  • OMER N/A
  • Industry
  • SEAT Industrial Machinery/Components
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • SEAT Industrials
  • OMER Health Care
  • Exchange
  • SEAT Nasdaq
  • OMER Nasdaq
  • Market Cap
  • SEAT 366.2M
  • OMER 188.1M
  • IPO Year
  • SEAT N/A
  • OMER 2009
  • Fundamental
  • Price
  • SEAT $1.86
  • OMER $3.20
  • Analyst Decision
  • SEAT Buy
  • OMER Strong Buy
  • Analyst Count
  • SEAT 11
  • OMER 5
  • Target Price
  • SEAT $4.49
  • OMER $18.00
  • AVG Volume (30 Days)
  • SEAT 1.4M
  • OMER 941.4K
  • Earning Date
  • SEAT 08-05-2025
  • OMER 08-06-2025
  • Dividend Yield
  • SEAT N/A
  • OMER N/A
  • EPS Growth
  • SEAT N/A
  • OMER N/A
  • EPS
  • SEAT N/A
  • OMER N/A
  • Revenue
  • SEAT $748,757,000.00
  • OMER N/A
  • Revenue This Year
  • SEAT N/A
  • OMER N/A
  • Revenue Next Year
  • SEAT $4.42
  • OMER $468.75
  • P/E Ratio
  • SEAT N/A
  • OMER N/A
  • Revenue Growth
  • SEAT 0.82
  • OMER N/A
  • 52 Week Low
  • SEAT $1.44
  • OMER $2.95
  • 52 Week High
  • SEAT $5.74
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • SEAT 51.89
  • OMER 41.04
  • Support Level
  • SEAT $1.60
  • OMER $2.95
  • Resistance Level
  • SEAT $1.94
  • OMER $3.25
  • Average True Range (ATR)
  • SEAT 0.13
  • OMER 0.23
  • MACD
  • SEAT 0.03
  • OMER 0.06
  • Stochastic Oscillator
  • SEAT 70.27
  • OMER 38.46

About SEAT Vivid Seats Inc.

Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: